The manufacturer of a sexual performance-enhancing supplement has announced a voluntary recall of the product, known as Liviro3. FDA lab analysis found the product contains the erectile dysfunction drug tadalafil, making Liviro3 an unapproved drug.
The manufacturer of a sexual performance-enhancing supplement has announced a voluntary recall of the product, known as Liviro3. FDA lab analysis found the product contains the erectile dysfunction drug tadalafil, making Liviro3 an unapproved drug.
During the voluntary recall process, the manufacturer discovered a counterfeit of its product on the market. Both Liviro3 and the counterfeit supplement are undergoing renewed independent testing.
A bulletin issued by FDA cautions consumers who have either the genuine or counterfeit product in their possession to stop using it immediately and to contact their physician if they have experienced any problem that may be related to using either product.
Serious adverse events stemming from the use of Ebek’s Liviro3 or counterfeit Liviro3 should be reported to FDA’s MedWatch Adverse Event Reporting program online (www.fda.gov/MedWatch/report.htm) or by calling 800-FDA-1088.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.